ALGS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

266.67K

-57.6%

-1.800

-86.26%

333.33K

+7.18%

-2.100

-141.02%

333.33K

-65.46%

-2.115

+38.24%

Estimates Revision

The market is revising Upward the revenue expectations for Aligos Therapeutics, Inc. (ALGS) for FY2025, with the revenue forecasts being adjusted by 11.34% over the past three months. During the same period, the stock price has changed by 4.03%.

Revenue Estimates for FY2025

Revise Upward

+11.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.6%

In Past 3 Month

Stock Price

Go Up

+4.03%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

50.00

Averages

50.00

High

50.00

Current: 0.000

Low

50.00

Averages

50.00

High

50.00

UBS

Michael Yee

Buy

initiated

$20

2026-01-07

New

Reason

UBS

Michael Yee

Price Target

$20

2026-01-07

New

initiated

Buy

Reason

UBS analyst Michael Yee initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $20 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

H.C. Wainwright

initiated

$50

2025-08-18

Reason

H.C. Wainwright

Price Target

$50

2025-08-18

initiated

Reason

H.C. Wainwright assumed coverage of Aligos Therapeutics with a Buy rating and $50 price target. The firm has conviction that ALG-000184 can become the new standard-of-care for chronic suppression of hepatitis B virus, while also serving as the oral backbone to future functional cure regimens.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$70

2025-03-31

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$70

2025-03-31

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$75 → $70

2025-03-11

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$75 → $70

2025-03-11

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Aligos Therapeutics Inc (ALGS.O) is -1.17, compared to its 5-year average forward P/E of -2.96. For a more detailed relative valuation and DCF analysis to assess Aligos Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.96

Current PE

-1.17

Overvalued PE

0.81

Undervalued PE

-6.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.38

Current EV/EBITDA

0.36

Overvalued EV/EBITDA

3.71

Undervalued EV/EBITDA

-10.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

61.81

Current PS

44.35

Overvalued PS

214.93

Undervalued PS

-91.31

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 162.3% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALGS News & Events

Events Timeline

No data

News

5.0

09:30 AMGlobenewswire

Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth

5.0

2025-12-12Globenewswire

Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan

5.0

2025-12-12Newsfilter

Aligos Grants 14,100 Stock Options to New Employees as Inducement

People Also Watch

Frequently Asked Questions

What is Aligos Therapeutics Inc (ALGS) stock price today?

The current price of ALGS is 10.33 USD — it has increased 7.05 % in the last trading day.

What is Aligos Therapeutics Inc (ALGS)'s business?

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

What is the price predicton of ALGS Stock?

What is Aligos Therapeutics Inc (ALGS)'s revenue for the last quarter?

Aligos Therapeutics Inc revenue for the last quarter amounts to 741.00K USD, decreased -41.61 % YoY.

What is Aligos Therapeutics Inc (ALGS)'s earnings per share (EPS) for the last quarter?

Aligos Therapeutics Inc. EPS for the last quarter amounts to -3.04 USD, decreased -0.98 % YoY.

What changes have occurred in the market's expectations for Aligos Therapeutics Inc (ALGS)'s fundamentals?

How many employees does Aligos Therapeutics Inc (ALGS). have?

Aligos Therapeutics Inc (ALGS) has 70 emplpoyees as of January 08 2026.

What is Aligos Therapeutics Inc (ALGS) market cap?

Today ALGS has the market capitalization of 63.57M USD.